Boston Scientific Co. (NYSE:BSX) Stake Lessened by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lowered its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 34.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 148,580 shares of the medical equipment provider's stock after selling 77,582 shares during the quarter. Edmond DE Rothschild Holding S.A.'s holdings in Boston Scientific were worth $13,271,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of BSX. Axiom Investors LLC DE grew its holdings in Boston Scientific by 208.2% in the fourth quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider's stock worth $335,167,000 after purchasing an additional 2,535,007 shares during the period. AIA Group Ltd lifted its position in Boston Scientific by 2,067.2% during the fourth quarter. AIA Group Ltd now owns 96,312 shares of the medical equipment provider's stock valued at $8,603,000 after purchasing an additional 91,868 shares during the period. Wellington Management Group LLP raised its stake in Boston Scientific by 10.2% during the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock valued at $3,230,293,000 after buying an additional 3,344,571 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in shares of Boston Scientific by 10.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 239,740 shares of the medical equipment provider's stock valued at $21,414,000 after buying an additional 23,605 shares during the period. Finally, Physician Wealth Advisors Inc. purchased a new position in shares of Boston Scientific in the 4th quarter worth $89,000. Institutional investors own 89.07% of the company's stock.

Remove Ads

Boston Scientific Stock Performance

Shares of NYSE BSX traded down $7.49 during trading hours on Friday, reaching $91.01. The stock had a trading volume of 9,643,789 shares, compared to its average volume of 7,260,449. The firm has a 50-day moving average of $102.14 and a 200-day moving average of $93.51. The firm has a market cap of $134.62 billion, a price-to-earnings ratio of 72.79, a PEG ratio of 2.79 and a beta of 0.77. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BSX. Raymond James raised their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Stifel Nicolaus upped their price objective on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their price target on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research note on Monday, March 3rd. Finally, Barclays upped their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and an average target price of $108.91.

Insider Buying and Selling

In other Boston Scientific news, EVP John Bradley Sorenson sold 6,528 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the sale, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Daniel J. Brennan sold 15,087 shares of the stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares in the company, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 133,183 shares of company stock valued at $13,948,476 over the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.